For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

In a review of 182 cancer studies, authors failed to report outcome data by sex in 90% of cases, even though men develop ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

For most screenable cancers, a pandemic-related surge of late-stage diagnoses in 2020 quickly returned to pre-pandemic levels in 2021, with the exception of cervical cancer.  According to the National ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...